This is an observational study enrolling patients with Solid Tumor cancers to identify genomic expression differences between exceptional responders and non-responders to standard of care chemotherapy. Data analysis of the gene expression profile of the exceptional responders compared to non-responders will define genomic patterns that may help understand their response to chemotherapy.
This is an observational study of patients with solid tumor cancer to identify genomic expression differences obtained from their circulating tumor cells between exceptional responders and non-responders to standard of care chemotherapy. This study requires a 10 mL heparinized peripheral blood sample from each study participant at the time of enrollment to isolate, enrich and profile circulating tumor cells. Data analysis of the gene expression profile will define genomic patterns using Nearest Template Prediction for a predetermined panel of therapeutic agents based on standard of care. Chemotherapy selection is physician-choice. Information regarding disease progression will be gathered. Data analysis will be performed in study participants in the setting of ongoing disease progression.
Study Type
OBSERVATIONAL
Enrollment
250
Physician's Choice Chemotherapy Treatment (non-guided)
The Pancreatic Cancer Treatment Center of Los Angeles
Los Angeles, California, United States
Identify exceptional responders with cancer to standard of care chemotherapy
Identify responders and non-responders
Time frame: 9 years
Correlation of genomic profiles from circulating cells with overall survival
Genomic expression profiles correlated with progression free and overall survival
Time frame: 9 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.